Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy

Cancer

Volumn 116, Issue 16, 2010, Pages 3969-3977

  Cianfrocca, Mary ^a   Lee, Sandra ^b   Von Roenn, Jamie ^a   Tulpule, Anil ^c   Dezube, Bruce J ^d   Aboulafia, David M ^e   Ambinder, Richard F ^f   Lee, Jeannette Y ^g   Krown, Susan E ^h   Sparano, Joseph A ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV) infection; Kaposi sarcoma; Paclitaxel; Pegylated liposomal doxorubicin

Indexed keywords

ANTIRETROVIRUS AGENT; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ZIDOVUDINE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEART DISEASE; HEMOGLOBINOPATHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION; KAPOSI SARCOMA; LEUKOPENIA; LUNG EMBOLISM; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; SWELLING; SYMPTOM; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VIRUS LOAD; WORK; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; DISEASE FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGY; SARCOMA, KAPOSI; VIROLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; SARCOMA, KAPOSI;

EID: 77956861383     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25362     Document Type: Article

References (32)

1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
2. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr.1999;21(suppl 1):S34-S41. (Pubitemid 29357647)
3. Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:270-274.
4. Sparano JA, Anand K, Desai J, et al. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr.1999;21(suppl 1):S18-S22.
5. Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer. 2003;103:142-144.
6. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399-402.
7. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
8. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load [letter]. N Engl J Med. 2007;357:1352-1353.
9. Krown SE, Lee JY, Dittmer DP; AIDS Malignancy Consortium. More on HIV-associated Kaposi's sarcoma [letter]. N Engl J Med. 2008;358:535-536.
10. Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). Int J STD AIDS. 2009;20:553-556.
11. Parkin DM, Sitas F, Chirenje M, et al. Part I: cancer in indigenous Africans-burden, distribution, and trends. Lancet Oncol. 2008;9:683-692. (Pubitemid 351878054)
12. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol.1998;16:2445-2451.
13. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683-691.
14. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
15. Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:1737-1740.
16. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95:147-154.
17. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16:1112-1121.
18. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS Malignancy Consortium study. J Clin Oncol. 2002;20:153-159.
19. Cella DF, McCain NL, Peterman AH, et al. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1996;5:450-453.
20. Peterman AH, Cella D, Mo F, et al. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997;6:572-584.
21. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
22. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol. 1989;7:1201-1207.
23. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
24. Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
25. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-197.
26. Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS. 1997;11:1653-1655.
27. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS. 1997;11:261-262.
28. Martinelli C, Zazzi M, Ambu S, et al. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpes-virus-8 during therapy with indinavir. AIDS. 1998;12:1717-1719.
29. Shaw A, McLean K. Kaposi sarcoma regression following treatment with a triple antiretroviral regimen containing nevaripine. Int J STD AIDS. 1999;10:417-418.
30. Niehues T, Horneff G, Megahed M, et al. Complete regression of AIDS-related Kaposi's sarcoma in AIDS. AIDS. 1999;13:1148-1149.
31. Murdaca G, Campelli A, Setti M, et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of 2 nucleoside reverse transcriptase inhibitors and 1 non-nucleoside reverse transcriptase inhibitor. AIDS. 2002;16:304-305.
32. Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001;19:573-580.